Finance Watch: Alphamab's $100m Series A Continues Theme Of Big Investments In China Biopharma
The Suzhou-based drug developer brings in new cash as US venture deals take a holiday. Also, France's Genfit may go public in the US, Taiwan Liposome launches its IPO, and Bioblast's strategic review ends in a reverse merger.
You may also be interested in...
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.
Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.